Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Elbasvir/Grazoprevir + Sofosbuvir in Cirrhotic HCV GT3
NCT02601573Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of elbasvir, grazoprevir in hepatitis C virus infection, sponsored by Merck & Co.. Started Jan 2016; status: completed.
02
Drugs
elbasvirgrazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02601573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601573.